Revolution Medicines Inc (NASDAQ:RVMD) — Market Cap & Net Worth
Market Cap & Net Worth: Revolution Medicines Inc (RVMD)
Revolution Medicines Inc (NASDAQ:RVMD) has a market capitalization of $18.62 Billion ($18.62 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1349 globally and #535 in its home market, demonstrating a 3.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Revolution Medicines Inc's stock price $139.48 by its total outstanding shares 193319805 (193.32 Million). Analyse cash flow conversion of Revolution Medicines Inc to see how efficiently the company converts income to cash.
Revolution Medicines Inc Market Cap History: 2020 to 2026
Revolution Medicines Inc's market capitalization history from 2020 to 2026. Data shows growth from $7.65 Billion to $26.96 Billion (28.82% CAGR).
Index Memberships
Revolution Medicines Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.77% | #21 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.05% | #160 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 1.12% | #14 of 263 |
Weight: Revolution Medicines Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Revolution Medicines Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Revolution Medicines Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
478.79x
Revolution Medicines Inc's market cap is 478.79 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $7.65 Billion | $42.98 Million | -$108.16 Million | 178.06x | N/A |
| 2021 | $4.87 Billion | $29.39 Million | -$187.09 Million | 165.56x | N/A |
| 2022 | $4.60 Billion | $35.38 Million | -$248.71 Million | 130.15x | N/A |
| 2023 | $5.54 Billion | $11.58 Million | -$436.37 Million | 478.79x | N/A |
Competitor Companies of RVMD by Market Capitalization
Companies near Revolution Medicines Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Revolution Medicines Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Revolution Medicines Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Revolution Medicines Inc's market cap moved from $7.65 Billion to $ 26.96 Billion, with a yearly change of 28.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $26.96 Billion | +75.12% |
| 2025 | $15.40 Billion | +82.10% |
| 2024 | $8.46 Billion | +52.51% |
| 2023 | $5.54 Billion | +20.40% |
| 2022 | $4.60 Billion | -5.36% |
| 2021 | $4.87 Billion | -36.42% |
| 2020 | $7.65 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Revolution Medicines Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.62 Billion USD |
| MoneyControl | $18.62 Billion USD |
| MarketWatch | $18.62 Billion USD |
| marketcap.company | $18.62 Billion USD |
| Reuters | $18.62 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more